StoneX Group’s ZyVersa Therapeutics ZVSA Stock Holding History

StoneX Group’s Portfolio ZVSA Stock Details ZVSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-36	Closed	-$3.12K	–	743
2023 Q2	$3.12K	Buy	+36	New	+$9.45K	﹤0.01%	592

Other funds holding ZVSA

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

WAG

Winthrop Advisory Group Boston, Massachusetts $1.48B AUM 22.62% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

StoneX Group's ZVSA Position: Q3 2023 in Review

StoneX Group sold out of ZyVersa Therapeutics (ZVSA) in Q3 2023, closing a stake of 36 shares — an estimated $3.12K sold.

StoneX Group first reported a position in ZVSA in Q2 2023 and held it in 1 quarter. The position peaked at $3.12K in Q2 2023. 9 funds tracked by Wall St. Rank hold ZVSA as of Q3 2023.

StoneX Group reported no remaining ZyVersa Therapeutics position as of Q3 2023 after selling out during the quarter.
StoneX Group sold 36 ZyVersa Therapeutics shares in Q3 2023, an estimated $3.12K.
StoneX Group first reported a position in ZyVersa Therapeutics in Q2 2023 and held it in 1 quarter.
StoneX Group's ZyVersa Therapeutics position peaked at $3.12K in Q2 2023.
9 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q3 2023.

Based on StoneX Group's 13F filing for Q3 2023, filed 15 Nov 2023.